close
Enquiry IconContact Us
Logo
  • Choose License Type

Global Cardiovascular Ultrasound Market, by Test Type (Transthoracic Echocardiogram, Transesophageal Echocardiogram, Stress Echocardiogram, and Others), by Technology (2D, 3D & 4D, and Doppler Imaging), by Modality (Portable and Standalone), by End User (Hospitals, Ambulatory Care Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1.41 billion in 2021 and is expected to exhibit a CAGR of 6.0% during the forecast period (2021-2028).

Increasing number of product launches or approvals is expected to boost the growth of the global cardiovascular ultrasound market. For instance, on January 27, 2021, Philips Healthcare, a leading medical technology company, launched the Philips Abdominal Aortic Aneurysm (AAA) Model, which provides physicians with a more patient-friendly solution for managing AAA patients than the current standard of care. Philips AAA Model delivers clinicians accurate diagnostic information without exposing patients to high levels of radiation and nephrotoxic contrast agents.

Increase in number of acquisitions, partnerships, and collaborations between market players is expected to propel the growth of the global cardiovascular ultrasound market during the forecast period. For instance, on May 10, 2021, DiA Imaging Analysis Ltd., a leading provider of AI-powered ultrasound analysis solutions, announced a collaboration with SonoScape Medical Corporation, a leading developer and manufacturer of ultrasound systems. SonoScape's ultrasound devices will be used to provide DiA's ultrasound artificial intelligence analysis solutions with the goal of reducing the variability associated with manual or visual analysis and increasing efficiency and accuracy throughout the analysis process.

Global Cardiovascular Ultrasound Market- Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic has affected several markets like elective surgeries and dermatology across the globe. The COVID-19 pandemic has affected the demand and supply of healthcare products in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and due to its financial impact on firms and financial markets.

However, impact of the coronavirus (COVID-19) pandemic is expected to drive the growth of the global cardiovascular ultrasound market, owing to increase in partnerships between market players for the cardiovascular ultrasound technology to be used in diagnosis and treatment of COVID-19. For instance, on November 12, 2020, Konica Minolta Healthcare Americas Inc., a multinational technology company, and DiA Imaging Analysis Ltd., a provider of advanced AI-based ultrasound technologies, announced the expansion of the LVivo Cardiac ultrasound artificial intelligence (AI) Toolbox on the Exa Cardio PACS platform. Exa users will have access to LVivo Toolbox, which will allow them to perform automated analysis of the left ventricle in COVID-19 patients in the echo lab and on the frontline, as recommended by the American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI).

Browse 35 Market Data Tables and 25 Figures spread through 210 Pages and in-depth TOC on Global Cardiovascular Ultrasound Market, by Test Type (Transthoracic Echocardiogram, Transesophageal Echocardiogram, Stress Echocardiogram, and Others), by Technology (2D, 3D & 4D, and Doppler Imaging), by Modality (Portable and Standalone), by End User (Hospitals, Ambulatory Care Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

To know the latest trends and insights prevalent in the global cardiovascular ultrasound market, click the link below:

https://www.coherentmarketinsights.com/market-insight/cardiovascular-ultrasound-market-4786

Key Takeaways of the Global Cardiovascular Ultrasound Market:

  • The global cardiovascular ultrasound market is expected to exhibit a CAGR of 6.0 % over the forecast period (2021-2028). North America is expected to account for major market share over the forecast period (2021-2028), owing to the rising product approvals by regulatory authorities. For instance, on January 6, 2021, the U.S. Food and Drug Administration (FDA) approved Ultromics' EchoGo Pro, an artificial intelligence (AI) powered, outcomes-driven decision support tool that can automatically identify coronary artery disease in echocardiograms. Ultromics is a global health technology company that is focused on providing autonomous echocardiography analysis through innovative AI (artificial intelligence) solutions.
  • Some of the major players operating in the global cardiovascular ultrasound market include GE Healthcare, Koninklijke Philips N.V., Siemens Healthcare GmbH, FUJIFILM Sonosite, Inc., Hitachi Medical Corporation, Samsung Medison Co., Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., CHISON Medical Technologies Co., Ltd., ESAOTE SPA, and Canon Medical Systems USA
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.